NAICS 325414: Biological Product
This U.S. industry comprises establishments primarily engaged in manufacturing vaccines, toxoids, blood fractions, and culture media of plant or animal origin (except diagnostic).

ExioML sector: Chemicals nec
Region: US | Year: 2022
Sector value added: 183879.917188 M EUR | Employment: 2033.54236812 thousand persons
Sector GHG emissions: 125728834468.0 kg CO2 eq | Energy carrier net total: 3186425.50957 TJ | Carbon intensity: 0.6837551179635024

Company: Glaxosmithkline Holdings
We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We prioritise innovation in vaccines and specialty medicines to prevent and treat disease.